Fig. 2.

Changes from baseline in fatigue as measured by Fatigue NRS (a) and BASDAI fatigue (b), as well as spinal pain at night through week 52 (c). Values are LSM from MMRM. Fatigue NRS—week 8: PBO, Nx = 101; IXE Q4W, Nx = 95; IXE Q2W, Nx = 101. Week 16: PBO, Nx = 99; IXE Q4W, Nx = 96; IXE Q2W, Nx = 98. Week 36: PBO, N = 39; IXE Q4W, Nx = 56; IXE Q2W, Nx = 58. Week 52: PBO, Nx = 34; IXE Q4W, Nx = 53; IXE Q2W; Nx = 52. BASDAI Fatigue and Spinal Pain at Night—week 1: PBO, Nx = 103; IXE Q4W, Nx = 95; IXE Q2W, Nx = 99. Week 2: PBO, Nx = 102; IXE Q4W, Nx = 96; IXE Q2W, Nx = 102. Weeks 4 and 8: PBO, Nx = 101; IXE Q4W, Nx = 96; IXE Q2W, Nx = 101. Weeks 12 and 16: PBO, Nx = 99; IXE Q4W, Nx = 96; IXE Q2W, Nx = 98. Week 20: PBO, Nx = 55; IXE Q4W, Nx = 68; IXE Q2W, Nx = 73. Week 24: PBO, Nx = 50; IXE Q4W, Nx = 64; IXE Q2W, Nx = 64. Week 28: PBO, Nx = 43; IXE Q4W, Nx = 63; IXE Q2W, Nx = 61. Week 32: PBO, Nx = 43; IXE Q4W, Nx = 59; IXE Q2W, Nx = 60. Week 36: PBO, Nx = 39; IXE Q4W, Nx = 56; IXE Q2W, Nx = 58. Week 44: PBO, Nx = 36; IXE Q4W, Nx = 54; IXE Q2W, Nx = 56. Week 52: PBO, Nx = 34; IXE Q4W, Nx = 53; IXE Q2W, Nx = 52. P values were from MMRM (treatment vs. placebo). *p < 0.05, ‡p < 0.01, †p < 0.001. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, IXE Q2W 80-mg ixekizumab every 2 weeks, IXE Q4W 80-mg ixekizumab every 4 weeks, LSM least squares mean, MMRM mixed-effect model for repeated measures, NRS numeric rating scale, Nx number of patients with non-missing values, PBO placebo